INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Olsson Shawn reported LENZ

Chief Commercial Officer · LENZ Therapeutics, Inc. · LENZ Therapeutics, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
84.2K
Price
—
Executed
Jan 2, 2026
Disclosed
Jan 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 6, 2026 disclosed

LENZ · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LENZ

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    50
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$64K
    7,500 sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    57
    SB
    Schimmelpennink Evert B.Director, President, CEO and Secretary
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$251K
    28.1K sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    51
    GP
    George Jeffrey P.Director
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$50K
    5,592 sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    84.2K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    5
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    16
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$108K
    4,212 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    11
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$21K
    10.0K sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    7
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    20
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$153K
    5,788 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    49
    MW
    Mccollum James WDirector
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$239K
    10.5K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    46
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$50K
    2,178 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    34
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$454
    20 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002015796-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 2, 2026
    Published
    Jan 6, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Olsson Shawn
    Role
    Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    LENZ Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    LENZ
    Shares
    84.2K
    Price per share
    $0
    Execution date (reported)
    Jan 2, 2026
    Owned after transaction
    84.2K shares
    Days from execution to publication
    4

    What this establishes

    Olsson Shawn filed this Form 4 reporting a grant or award of LENZ on Jan 2, 2026. It became public on Jan 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Olsson Shawncik:0002015796
    Issuer
    LENZ Therapeutics, Inc.cik:0001815776

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.